Articles tagged with Cancer Cells
Researchers have identified a new adaptor protein on the microtubule roadway that helps motors navigate proteins to their correct destinations. This discovery challenges previous assumptions about motor function and has implications for understanding diseases such as cancer and cardiac disease.
Researchers developed an artificial structure that can switch on immune cells to target and destroy cancer cells. The system mimics the cell membrane of antigen-presenting cells, which are responsible for activating immune responses against cancer.
The study found that KTE-C19 induced a significant response rate in patients with diffuse large B-cell lymphoma, with 76% overall response and 47% complete remission. Serious adverse events were reported, but the team developed guidelines to manage side effects across multiple institutions.
The latest ASCB celldance videos offer an immersive look at living cells through powerful imaging technologies. The three selected labs showcased their research using innovative storytelling methods, including spoken word and animation. The videos provide a glimpse into the intricate cellular dance of life.
A group of 12 high-risk acute myeloid leukemia patients who received genetically engineered immune cells are still in remission after over two years. The treatment was successful in recognizing and destroying cancer cells, with no relapse observed in this cohort.
A metabolite called D-2-hydroxyglutarate (D-2HG) has been identified as a promising target for future cancer therapies due to its ability to promote cancer cell transformation and increase the likelihood of tumor spread in colorectal cancer patients.
The discovery of EphA2 as a receptor for progranulin sheds light on its role in cancer and neurodegenerative diseases. Progranulin binding activates cellular pathways that promote cancer cell aggression, while also triggering a positive feedback loop that increases progranulin secretion.
Researchers identified a molecule called AXL which triggers the spread of an aggressive form of ovarian cancer. Blocking AXL may be an effective treatment option for patients with Mes subtype ovarian cancer.
Researchers at the University of York and Texas have identified a protein, PAQR11, in the Golgi apparatus that receives a signal from Zeb1, triggering the transport of membrane sacks and altering the cancer cell's perimeter. This process allows cancer cells to detach from their fixed position and travel to other parts of the body.
Researchers at the University of Southampton have engineered human cells with a genetic circuit that produces a molecule inhibiting HIF-1, allowing cancer cells to survive in nutrient-limited environments. The study demonstrates the potential for using sentinel circuits to target diseases like cancer.
A study published in Nature Cell Biology reveals a pro-growth signaling pathway common to many cancers that can be targeted with precision, leading to the efficient killing of cancer cells while leaving healthy cells unaffected. The researchers identified a scaffolding protein IQGAP1 as a key player in this pathway.
Researchers capture elusive DNA reaction intermediates in living cells, discovering mechanisms underlying genome instability and a new role for an E. coli protein related to human cancer proteins. This breakthrough could lead to the development of new drugs that prevent cancer by neutralizing these key pieces of genetic code.
Arecoline, an analog of nicotine, has been identified as an inhibitor of the enzyme ACAT1, which contributes to the Warburg effect in cancer cells. Researchers found that arecoline steers cells' metabolism away from glycolysis, inhibiting growth in human lung cancer and leukemia cells.
Restoring dysfunctional blood vessels in tumors can prevent cancer cells from spreading and improve chemotherapy delivery. Healthy tumor vessels also enhance the supply of immune cells, which is crucial for emerging immunotherapy treatments.
Scientists have established comprehensive maps of the human epigenome, revealing how genes are active in specific cells. The maps, published by the International Human Epigenome Consortium, provide insights into cellular differentiation and potential new treatments for diseases.
A new study by TSRI researchers suggests that disruptions in circadian rhythms may leave levels of an important cancer-linked protein, called cMYC, unchecked. This connection has significant implications for the link between daily rhythms and cell growth.
A study by the University of Leeds found that Reovirus, a common childhood cough virus, can stimulate the body's immune system to kill off liver cancer cells and the hepatitis C virus. The researchers hope to start clinical trials to test its effectiveness in treating primary liver cancer.
Researchers have developed a new cancer treatment called photoimmunotherapy that combines the immune system with laser energy to target and destroy cancer cells. This innovative technique delivers precise, lethal payloads with minimal collateral damage.
A multidisciplinary international team of scientists solved the mystery of ferroptosis, a type of controlled cell death that uses iron to safely destroy and recycle malfunctioning cells. The study aims to develop potential therapies for conditions like radiation injury, cancer and radiation-induced cellular damage.
Researchers at CHLA are developing a new treatment approach for patients with relapsed acute lymphoblastic leukemia (ALL) by targeting the molecule integrin alpha4, which shelters leukemia cells from chemotherapy. The goal is to develop a novel inhibitor of this molecule for clinical use.
A new 'sponge on a string' pill test has been shown to accurately identify people with Barrett's oesophagus who are at low risk of developing oesophageal cancer. This non-invasive test may replace uncomfortable endoscopies for some patients, allowing them to be monitored instead.
Researchers at the University of Pittsburgh Cancer Institute discovered that cancer cells exploit a previously unknown mechanism called alternative lengthening of telomeres (ALT) to reset their telomere clocks. This allows them to continue dividing and growing, making them more aggressive and resistant to treatment.
A systematic review of seven studies found that low vitamin D levels are associated with an increased risk of bladder cancer. Vitamin D deficiency may be a key factor in preventing the cells within the bladder from stimulating an adequate immune response to abnormal cells, suggesting a potential mechanism for cancer prevention.
Pitt researchers discovered how oxidative stress accelerates telomere shortening by damaging DNA precursor molecules. This finding offers a new way to inhibit telomerase activity, potentially treating cancer. The study also reveals that oxidative stress can promote telomere lengthening.
A team of researchers discovered that immune T cells have two internal clocks controlling their lifespan and division, shedding new light on how the body regulates immune responses. The discovery also explains how errors in these clocks may lead to immune cell cancers such as leukaemia and lymphoma.
Researchers at the University of Georgia have discovered a drug combination that targets mitotic slippage, allowing for complete cell death and improving chemotherapy's effectiveness. The study focuses on inactivating CRL2-ZYG11, which promotes mitosis, and has potential to treat various cancers.
Researchers at Uppsala University developed a new approach to study cancer cells' reactions to treatments, enabling the identification of promising drug combinations. 3D tumor models mimic real-world conditions, where cancer cells have limited access to nutrients and oxygen.
Researchers discovered CD98 promotes AML, a type of aggressive cancer, and inhibiting it with the anti-CD98 antibody IGN523 blocks AML growth in patient-derived cells and mouse models.
Researchers found thousands of genetic translocations in both healthy and cancerous mouse cells, highlighting the importance of considering individual genetic backgrounds. By using 'de novo assembly', scientists can compare a patient's cancer cells to their own healthy cells, reducing errors in translocation discovery.
Researchers have broken down lung cancer into distinct subtypes with unique molecular profiles, suggesting potential for personalized therapies. The study identifies specific subsets of cancer cells that may be responsive to immunotherapy, a promising approach for treating the disease.
Researchers develop universal assay to detect cisplatin cross-linking sites in the genome. They found that mitochondrial DNA is a major target of cisplatin's action, while nuclear DNA is less affected.
Researchers use fission yeast to discover new cancer drugs targeting active proteins involved in DNA replication. The unique "arched and snapped" appearance of treated cells suggests potential for accelerating drug development.
Scientists at TUM have discovered new mechanisms of action for Imiquimod, a medication used to treat viral skin infections and certain types of skin cancer. The study reveals that Imiquimod activates the NLRP3 inflammasome, which can lead to inflammation and potentially contribute to its efficacy or adverse side effects.
A new treatment plan combining multiple targeted drugs for CML has the potential to increase life expectancy and reduce relapse risk. Mathematical modeling predicts optimal combination schedules based on tumor mutations, offering a personalized approach to cancer treatment.
Researchers found a way to break up p97 complex into its subunits using ASPL protein, which could be a promising new approach to kill proliferating cancer cells. This discovery may lead to the identification of smaller molecules that can disrupt the structure of p97 in a targeted manner.
Researchers identified amino acid valine as crucial for hematopoietic stem cell maintenance. A valine-free diet with gradual reintroduction led to successful long-term engraftment of healthy donor cells in mice.
Researchers used CRISPR to identify genes essential for AML cell survival, including the novel KAT2A gene. Inhibition of KAT2A destroys AML cells while sparing healthy blood cells in laboratory and mouse studies, offering new potential treatment options.
Researchers discovered that leukemia cells don't hide in specific niches but instead move actively throughout the bone marrow. This movement may help them survive treatment and evade targeted therapies.
Quiescent human cells exhibit an inflammatory profile similar to acute infections when energetically stressed, suggesting a pro-survival strategy may not be well-suited for long-term chronic stresses. This could impair genome repair and increase cancer risk.
Researchers will study cellular and molecular mechanisms of lung regeneration, targeting AT2 cells with gene editing techniques to correct disease-causing mutations and promote repair.
Researchers pinpoint a unique metabolic reprogramming in cancer cells that enables their ability to biosynthesize and replicate, and may provide new treatment opportunities. By blocking specific enzymes involved in this process, tumor growth can be slowed or stopped in preclinical tests.
Scientists at the University of Birmingham discovered a previously unknown mechanism connecting transcription machinery to genetic mutations in aggressive cancer cells. The research found that increased transcription activity leads to R-loop formation, causing DNA damage and replication stress.
Researchers at Johns Hopkins Medicine identified a protein that enables toxic alpha-synuclein aggregates to spread in the brain. A treatment strategy blocking this protein's action may slow Parkinson's disease progression, as antibodies already in clinical trials for cancer therapy show protective effects.
Researchers identified genes that control cellular senescence, a process that permanently arrests cell growth. These findings have potential applications for creating new anticancer drugs and developing anti-aging products.
Researchers discovered that certain proteins associated with Alzheimer's disease are stored in dormant cancer cells as amyloid bodies. Disaggregation of these bodies can reactivate the cancer cells. The study identified ribosomal intergenic noncoding RNA as a target for drug discovery to prevent amyloid body disaggregation.
Researchers have discovered a fluid behaving like water when trapped in a nanocage of a porous solid, offering new insights into nanoscale behavior. This breakthrough may lead to the design of machines with specific functions, including medical applications and molecular electronics.
Engineering researchers at the University of Texas at Austin have developed a new method for delivering chemotherapy directly and efficiently to individual cells using nanoparticles called 'connectosomes.' This approach has been shown to reduce the dose required to kill cancer cells by up to 10 times, potentially decreasing side effects.
Multiple myeloma cells communicate with healthy bone marrow cells, altering protein translation initiation to create a favorable environment for cancer growth. This crosstalk allows tumor cells to modify the surrounding microenvironment, promoting progression and disease.
Researchers at Johns Hopkins University School of Medicine have developed a new compound by attaching glucose to triptolide, making it more effective against cancer cells. The compound, glutriptolide 2, shows promise as a potential anticancer treatment with fewer side effects.
Researchers identified molecules controlling cell repulsion through endocytosis, a process by which cells engulf neighboring protein complexes. This discovery provides insight into development and neuronal networks, as well as cancer growth and metastasis.
Researchers have identified a specific signaling pathway in leukemia cells that enhances their viability and reproduction. The discovery highlights the potential for targeting this pathway to develop new treatments for acute lymphoblastic leukemia (T-ALL).
Tiny immune receptors on T-cells recognize antigens more effectively when clustered together, leading to improved immune response. This discovery could lead to new strategies to reprogram inactive T-cells and improve treatment for cancer and deadly infections.
Scientists have discovered a mechanism of intercellular communication that helps explain how biological systems function properly. The findings shed light on the poorly-understood interaction between cells and suggest that cancer cells' poor communication contributes to their biologic damage.
Researchers from Case Western Reserve University identified structurally abnormal genes in esophageal adenocarcinoma, which could serve as potential indicators of aggressive esophageal adenocarcinoma. The study found gene fusions that were highly associated with poorer patient survival and may aid tumor development.
Scientists at Johns Hopkins have discovered a drug combination that specifically targets the metabolic pathways of pancreatic cancer cells. By combining an experimental drug with metformin, researchers were able to shrink tumors by at least 50% in animal models, providing new evidence for treating this aggressive form of cancer.
Researchers created novel scaffolds with aligned ceramic nanofibers to control stem cell development and cancer cell behavior. The unique hybrid nano-network selectively guides stem cells towards specific lineages while suppressing inflammatory factors in cancer cells.
Fascin protein plays a crucial role in deforming the cell nucleus to navigate through tight spaces. The study suggests that this ability may be exploited by cancer cells to invade tissues, making fascin a potential target for therapy.
A new study by Queen Mary University of London found that certain Barrett's Oesophagus cells can be identified as 'born to be benign' or 'bad', allowing for early detection and prevention of oesophageal cancer. The test uses genetic analysis of individual cells, predicting future risk regardless of time since abnormal cell appearance.
Cancer cells counteract telomere breakdown by building them up with the enzyme telomerase. A new study using CRISPR gene editing technology reveals telomerase's mechanism, allowing scientists to identify potential targets for anti-cancer drugs.
Researchers at the University of Manchester have discovered a new test that can detect cancerous cells in the blood, offering a promising breakthrough in diagnosing and treating childhood leukemia. The test uses special structures called extracellular vesicles that are released by cancer cells and can be traced in the blood.